Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Management Engineering, College of Business, Korea Advanced Institute of Science and Technology, Seoul, Korea.
Korean J Intern Med. 2023 Mar;38(2):248-253. doi: 10.3904/kjim.2022.135. Epub 2023 Jan 17.
BACKGROUND/AIMS: The recent coronavirus disease 2019 (COVID-19) pandemic has been associated with changes in the epidemiology of not only infectious diseases but also several non-infectious conditions. This study investigated changes in the recorded incidence of various rheumatic diseases during the COVID-19 pandemic.
The number of patients for each disease from January 2016 to December 2020 was obtained from the Korean Health Insurance Review and Assessment Service database. We compared the incidence of nine rheumatic diseases (seropositive rheumatoid arthritis, systemic lupus erythematosus [SLE], idiopathic inflammatory myositis [IIM], ankylosing spondylitis [AS], systemic sclerosis, Sjögren's syndrome, Behçet's disease [BD], polymyalgia rheumatica, and gout) and hypertensive diseases to control for changes in healthcare utilisation before and after the COVID-19 outbreak. The disease incidence before and after the COVID-19 outbreak was compared using the autoregressive integrated moving average (ARIMA) and quasi- Poisson analyses.
Compared with the predicted incidence in 2020 using the ARIMA model, the monthly incidence of SLE, BD, AS, and gout temporarily significantly decreased, whereas other rheumatic diseases and hypertensive diseases were within the 95% confidence interval (CI) of the predicted values in the first half of 2020. In age- and sex-adjusted quasi-Poisson regression analysis, the annual incidences of IIM (rate ratio [RR], 0.473; 95% CI, 0.307 to 0.697), SLE (RR, 0.845; 95% CI, 0.798 to 0.895), and BD (RR, 0.850; 95% CI, 0.796 to 0.906) were significantly decreased compared with those in the previous 4 years.
The recorded annual incidence of some rheumatic diseases, including IIM, SLE, and BD, decreased during the COVID-19 pandemic.
背景/目的：新冠疫情不仅改变了传染病的流行病学，也改变了多种非传染性疾病。本研究旨在调查新冠疫情期间各种风湿性疾病的记录发病率变化。
从韩国健康保险审查和评估服务数据库中获取 2016 年 1 月至 2020 年 12 月的每位患者的疾病数量。我们比较了 9 种风湿性疾病（血清阳性类风湿关节炎、系统性红斑狼疮[SLE]、特发性炎性肌病[IIM]、强直性脊柱炎[AS]、系统性硬化症、干燥综合征、贝赫切特病[BD]、巨细胞动脉炎和痛风）和高血压疾病的发病率，以控制新冠疫情前后医疗保健利用的变化。使用自回归综合移动平均（ARIMA）和拟泊松分析比较新冠疫情前后的疾病发病率。
与 ARIMA 模型预测的 2020 年发病率相比，SLE、BD、AS 和痛风的月发病率暂时显著降低，而其他风湿性疾病和高血压疾病的发病率在 2020 年上半年均在预测值的 95%置信区间（CI）内。在年龄和性别调整的拟泊松回归分析中，IIM（发病率比[RR]，0.473；95%CI，0.307 至 0.697）、SLE（RR，0.845；95%CI，0.798 至 0.895）和 BD（RR，0.850；95%CI，0.796 至 0.906）的年发病率与前 4 年相比显著降低。
新冠疫情期间，包括 IIM、SLE 和 BD 在内的一些风湿性疾病的记录发病率降低。
